NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

245.76B

Vuru Grade

68.09/100

Current Price

$102.46
-0.85 (-0.82%)

Growth Price

$64.04
Overvalued by 37.49%

Stability Price

$21.84
Overvalued by 78.68%

Company Metrics

  • 24.81 P/E
  • 4.62 P/S
  • 3.5 P/B
  • 4.13 EPS
  • 12.42% Cash ROIC
  • 0.51 Cash Ratio
  • 2.82 / 2.8% Dividend
  • 1.76M Avg. Vol.
  • 2.40B Shares
  • 245.76B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Teva Pharmaceutical Industries (TEVA) Falls On FDA Approval For Novartis AG ...
Bidness ETC - Apr 17, 2015
The generic Copaxone, which has received approval for 20 mg strength, has been developed by Sandoz, the generic drug-making subsidiary of Novartis AG (ADR) (NYSE:NVS). The generic version has been labeled as a “substitutable” drug for Copaxone, ...
Novartis AG (ADR) (NVS)'s Arzerra In Combination With Chlorambucil Shows 71 ...
Bidness ETC - Apr 15, 2015
Patients suffering with chronic lymphocytic leukemia (CLL) have a hope, in chemotherapy combination drugs Arzerra, and chlorambucil.
Novartis AG (ADR) To Pay $12.3 Million To Juno In CAR-T Patent Settlement
Bidness ETC - Apr 7, 2015
Novartis AG (ADR) (NYSE:NVS) has finally reached a cancer immunotherapy patent settlement with Juno Therapeutics Inc (NASDAQ:JUNO) after a three-year-long dispute, paving way for both companies to enhance their efforts in developing potential ...
Novartis AG (ADR) (NVS) And Juno Therapeutics Inc (JUNO) Reach Mutual ... - InvestCorrectly
BMJ Says Novartis AG (ADR) Hindered Trials That Pitted Lucentis Against ...
Bidness ETC - Apr 7, 2015
Novartis AG (ADR) (NYSE:NVS) has been accused of thwarting publicly-funded UK-based trials that attempted to test the safety and efficacy of Avastin, a cheaper potential alternative therapy, to Novartis' eye drug Lucentis for the treatment of wet age ...
Arrowhead Research Corp To Acquire Novartis AG (ADR) RNAi Assets
Bidness ETC - Mar 6, 2015
Arrowhead Research Corp (NASDAQ:ARWR), which develops targeted RNAi therapeutics, announced Thursday that it will acquire Novartis AG's (ADR) (NYSE:NVS) RNAi research and development portfolio and other assets in efforts to strengthen its work in ...
Small Cap Stocks Under Consideration - Arrowhead Research (ARWR),Neustar ... - Investor Wired
Stocks in Momentum: Arrowhead Research Corp. (NASDAQ:ARWR), Vertex ... - StreetWise Report
Trade of the Day: Pullback in NVS Stock Could Yield 15%-Plus Profits
Investorplace.com - Jan 30, 2015
Novartis AG (ADR) (NYSE:NVS) - This Switzerland-based health care company is a leading international provider of pharmaceuticals, generic drugs, and consumer and animal health products.
Novartis AG (ADR) Inks $750 Million Deal With Aduro Biotech
Bidness ETC - Mar 31, 2015
Novartis AG (ADR) (NYSE:NVS) is betting $750 million on what appears to be a promising therapeutic approach from Aduro Biotech, as it tries to broaden its cancer immunotherapy research.
Novartis AG (ADR) Partners With Aduro Biotech With A $750 Million Deal - Business Finance News
Novartis AG (ADR) Zarxio Becomes First Biosimilar Approved For Sale In US
Bidness ETC - Mar 9, 2015
Novartis AG (ADR) (NYSE:NVS) on Friday won the US Food and Drug Administration's (FDA) approval for its biosimilar drug Zarxio, a cheaper imitation version of Amgen, Inc.'s (NASDAQ:AMGN) Neupogen, making Zarxio the first ever biosimilar to be ...
GlaxoSmithKline plc (ADR) And Novartis AG (ADR) Complete Three-Part Deal ...
Bidness ETC - Mar 2, 2015
GlaxoSmithKline plc (ADR) (NYSE:GSK) and Novartis AG (ADR) (NYSE:NVS) announced on Monday that the two companies have completed a series of complicated asset swaps worth $20 billion, in what appears to be a move to tidy up asset portfolios to ...
Asset Swaps Of Novartis AG (ADR) (NYSE:NVS) and GlaxoSmithKline plc (ADR ... - Stocks.org
GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge - FiercePharma
GlaxoSmithKline plc (ADR) To Close Asset Swap Deal With Novartis AG (ADR ...
Bidness ETC - Feb 26, 2015
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced on Wednesday that it anticipates closing the mega-billion dollar asset exchange with Novartis AG (ADR) (NYSE:NVS) in the week beginning March 2, 2015. However, the deal, which is expected to make ...
Novartis AG (NYSE:NVS) & GlaxoSmithKline PLC (NYSE:GSK) Receive a Green ... - WallStreet.org